References
1. Mathews V, George B, Viswabandya A, et al. Improved clinical outcomes
of high risk β thalassemia major patients undergoing a HLA matched
related allogeneic stem cell transplant with a treosulfan based
conditioning regimen and peripheral blood stem cell grafts. PloS
One . 2013;8(4):e61637. doi:10.1371/journal.pone.0061637
2. Lucarelli G, Galimberti M, Delfini C, et al. MARROW TRANSPLANTATION
FOR THALASSAEMIA FOLLOWING BUSULPHAN AND CYCLOPHOSPHAMIDE. The
Lancet . 1985;325(8442):1355-1357. doi:10.1016/S0140-6736(85)91784-2
3. George B, Viswabandya A, Abraham A, et al. Increased Incidence of
Mixed Chimerism with the Use of Fludarabine – Treosulfan Based
Conditioning in Patients Undergoing Allogeneic Stem Cell Transplantation
for Thalassaemia Major. Biol Blood Marrow Transplant .
2015;21(2):S284-S285. doi:10.1016/j.bbmt.2014.11.451
4. George B, Abraham A, Lakshmi K, et al. Treosulfan Based Conditioning
Regimen Is Associated with Better Overall Survival Compared to Busulfan
Based Regimens in Older Children with Thalassaemia Major. Biol
Blood Marrow Transplant . 2019;25(3, Supplement):S317-S318.
doi:10.1016/j.bbmt.2018.12.649
5. Salinger DH, Blough DK, Vicini P, et al. A limited sampling schedule
to estimate individual pharmacokinetic parameters of fludarabine in
hematopoietic cell transplant patients. Clin Cancer Res Off J Am
Assoc Cancer Res . 2009;15(16):5280-5287.
doi:10.1158/1078-0432.CCR-09-0427
6. McCune JS, Woodahl EL, Furlong T, et al. A pilot pharmacologic
biomarker study of busulfan and fludarabine in hematopoietic cell
transplant recipients. Cancer Chemother Pharmacol .
2012;69(1):263-272. doi:10.1007/s00280-011-1736-3
7. Long-Boyle JR, Green KG, Brunstein CG, et al. High fludarabine
exposure and relationship with treatment-related mortality after
nonmyeloablative hematopoietic cell transplantation. Bone Marrow
Transplant . 2011;46(1):20-26. doi:10.1038/bmt.2010.53
8. Sanghavi K, Wiseman A, Kirstein MN, et al. Personalized fludarabine
dosing to reduce nonrelapse mortality in hematopoietic stem-cell
transplant recipients receiving reduced intensity conditioning.Transl Res J Lab Clin Med . 2016;175:103-115.e4.
doi:10.1016/j.trsl.2016.03.017
9. Mohanan E, Panetta JC, Lakshmi KM, et al. Population pharmacokinetics
of fludarabine in patients with aplastic anemia and Fanconi anemia
undergoing allogeneic hematopoietic stem cell transplantation.Bone Marrow Transplant . Published online May 8, 2017.
doi:10.1038/bmt.2017.79
10. Ivaturi V, Dvorak CC, Chan D, et al. Pharmacokinetics and
Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric
Hematopoietic Cell Transplant Recipients. Biol Blood Marrow
Transplant J Am Soc Blood Marrow Transplant . 2017;23(10):1701-1713.
doi:10.1016/j.bbmt.2017.06.021
11. Langenhorst JB, Dorlo TPC, van Maarseveen EM, et al. Population
Pharmacokinetics of Fludarabine in Children and Adults during
Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.Clin Pharmacokinet . 2019;58(5):627-637.
doi:10.1007/s40262-018-0715-9
12. Scheulen ME, Hilger RA, Oberhoff C, et al. Clinical phase I dose
escalation and pharmacokinetic study of high-dose chemotherapy with
treosulfan and autologous peripheral blood stem cell transplantation in
patients with advanced malignancies. Clin Cancer Res Off J Am
Assoc Cancer Res . 2000;6(11):4209-4216.
13. Casper J, Freund M. Treosulfan based conditioning for autologous and
allogeneic hematopoietic stem cell transplantation. Int J Clin
Pharmacol Ther . 2004;42(11):661-662.
14. Hilger RA, Baumgart J, Scheulen ME, et al. Pharmacokinetics of
treosulfan in a myeloablative combination with cyclophosphamide prior to
allogeneic hematopoietic stem cell transplantation. Int J Clin
Pharmacol Ther . 2004;42(11):654-655.
15. Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with
treosulfan and fludarabine followed by allogeneic hematopoietic cell
transplantation for high-risk hematologic malignancies. Biol Blood
Marrow Transplant J Am Soc Blood Marrow Transplant . 2011;17(3):341-350.
doi:10.1016/j.bbmt.2010.05.007
16. Główka FK, Romański M, Teżyk A, Zaba C, Wróbel T. HPLC method for
determination of biologically active epoxy-transformers of treosulfan in
human plasma: pharmacokinetic application. J Pharm Biomed Anal .
2012;62:105-113. doi:10.1016/j.jpba.2011.12.021
17. ten Brink MH, Ackaert O, Zwaveling J, et al. Pharmacokinetics of
Treosulfan in Pediatric Patients Undergoing Hematopoietic Stem Cell
Transplantation: Ther Drug Monit . Published online January
2014:1. doi:10.1097/FTD.0000000000000047
18. Główka F, Kasprzyk A, Romański M, et al. Pharmacokinetics of
treosulfan and its active monoepoxide in pediatric patients after
intravenous infusion of high-dose treosulfan prior to HSCT. Eur J
Pharm Sci Off J Eur Fed Pharm Sci . 2015;68:87-93.
doi:10.1016/j.ejps.2014.12.010
19. Koyyalamudi SR, Kuzhiumparambil U, Nath CE, et al. Development and
Validation of a High Pressure Liquid Chromatography–UV Method for the
Determination of Treosulfan and Its Epoxy Metabolites in Human Plasma
and Its Application in Pharmacokinetic Studies. J Chromatogr Sci .
2016;54(3):326-333. doi:10.1093/chromsci/bmv145
20. Bartelink IH, van Reij EML, Gerhardt CE, et al. Fludarabine and
exposure-targeted busulfan compares favorably with
busulfan/cyclophosphamide-based regimens in pediatric hematopoietic cell
transplantation: maintaining efficacy with less toxicity. Biol
Blood Marrow Transplant J Am Soc Blood Marrow Transplant .
2014;20(3):345-353. doi:10.1016/j.bbmt.2013.11.027
21. Perkins JB, Kim J, Anasetti C, et al. Maximally tolerated busulfan
systemic exposure in combination with fludarabine as conditioning before
allogeneic hematopoietic cell transplantation. Biol Blood Marrow
Transplant J Am Soc Blood Marrow Transplant . 2012;18(7):1099-1107.
doi:10.1016/j.bbmt.2011.12.584
22. Russell JA, Kangarloo SB, Williamson T, et al. Establishing a target
exposure for once-daily intravenous busulfan given with fludarabine and
thymoglobulin before allogeneic transplantation. Biol Blood Marrow
Transplant J Am Soc Blood Marrow Transplant . 2013;19(9):1381-1386.
doi:10.1016/j.bbmt.2013.07.002
23. McCune JS, Jacobson P, Wiseman A, Militano O. Optimizing drug
therapy in pediatric SCT: focus on pharmacokinetics. Bone Marrow
Transplant . 2015;50(2):165-172. doi:10.1038/bmt.2014.235
24. Mathews V, George B, Deotare U, et al. A new stratification strategy
that identifies a subset of class III patients with an adverse prognosis
among children with beta thalassemia major undergoing a matched related
allogeneic stem cell transplantation. Biol Blood Marrow Transplant
J Am Soc Blood Marrow Transplant . 2007;13(8):889-894.
doi:10.1016/j.bbmt.2007.05.004
25. Fouzia NA, Edison ES, Lakshmi KM, et al. Long-term outcome of mixed
chimerism after stem cell transplantation for thalassemia major
conditioned with busulfan and cyclophosphamide. Bone Marrow
Transplant . 2018;53(2):169-174. doi:10.1038/bmt.2017.231
26. Common Terminology Criteria for Adverse Events (CTCAE) |
Protocol Development | CTEP. Accessed October 13, 2020.
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_60
27. Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT
Handbook: Hematopoietic Stem Cell Transplantation and Cellular
Therapies . 7th ed. Springer; 2019. Accessed October 13, 2020.
http://www.ncbi.nlm.nih.gov/books/NBK553942/
28. Wang X. Firth logistic regression for rare variant association
tests. Front Genet . 2014;5. doi:10.3389/fgene.2014.00187
29. Bornhäuser M, Storer B, Slattery JT, et al. Conditioning with
fludarabine and targeted busulfan for transplantation of allogeneic
hematopoietic stem cells. Blood . 2003;102(3):820-826.
doi:10.1182/blood-2002-11-3567
30. Bonin M, Pursche S, Bergeman T, et al. F-ara-A pharmacokinetics
during reduced-intensity conditioning therapy with fludarabine and
busulfan. Bone Marrow Transplant . 2007;39(4):201-206.
doi:10.1038/sj.bmt.1705565
31. Bemer MJ, Sorror M, Sandmaier BM, O’Donnell PV, McCune JS. A pilot
pharmacologic biomarker study in HLA-haploidentical hematopoietic cell
transplant recipients. Cancer Chemother Pharmacol .
2013;72(3):607-618. doi:10.1007/s00280-013-2232-8
32. McCune JS, Vicini P, Salinger DH, et al. Population
pharmacokinetic/dynamic model of lymphosuppression after fludarabine
administration. Cancer Chemother Pharmacol . 2015;75(1):67-75.
doi:10.1007/s00280-014-2618-2
33. McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S.
Association of fludarabine pharmacokinetic/dynamic biomarkers with donor
chimerism in nonmyeloablative HCT recipients. Cancer Chemother
Pharmacol . 2015;76(1):85-96. doi:10.1007/s00280-015-2768-x
34. Chung H, Hong KT, Lee JW, et al. Pharmacokinetics of fludarabine and
its association with clinical outcomes in paediatric haematopoietic stem
cell transplantation patients. Bone Marrow Transplant .
2019;54(2):284-292. doi:10.1038/s41409-018-0260-z
35. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of
oral busulphan in children with beta thalassaemia major undergoing
allogeneic bone marrow transplantation. Bone Marrow Transplant .
1999;24(1):5-11. doi:10.1038/sj.bmt.1701814
36. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized
trial of two different conditioning regimens for bone marrow
transplantation in thalassemia–the role of busulfan pharmacokinetics
in determining outcome. Bone Marrow Transplant .
2005;36(10):839-845. doi:10.1038/sj.bmt.1705151
37. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior
of intravenous busulfan in children with thalassemia undergoing
hematopoietic stem cell transplantation: a prospective evaluation of
pharmacokinetic and pharmacodynamic profile with therapeutic drug
monitoring. Blood . 2010;115(22):4597-4604.
doi:10.1182/blood-2010-01-265405
38. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R.
Glutathione S-transferase activity influences busulfan pharmacokinetics
in patients with beta thalassemia major undergoing bone marrow
transplantation. Drug Metab Dispos Biol Fate Chem .
2001;29(3):264-267.
39. Chiesa R, Cappelli B, Crocchiolo R, et al. Unpredictability of
Intravenous Busulfan Pharmacokinetics in Children Undergoing
Hematopoietic Stem Cell Transplantation for Advanced Beta Thalassemia:
Limited Toxicity with a Dose-Adjustment Policy. Biol Blood Marrow
Transplant . 2010;16(5):622-628. doi:10.1016/j.bbmt.2009.11.024
40. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A.
Evaluation of existing limited sampling models for busulfan kinetics in
children with beta thalassaemia major undergoing bone marrow
transplantation. Bone Marrow Transplant . 2001;28(9):821-825.
doi:10.1038/sj.bmt.1703245
41. Balasubramanian P, Desire S, Panetta JC, et al. Population
pharmacokinetics of cyclophosphamide in patients with thalassemia major
undergoing HSCT. Bone Marrow Transplant . 2012;47(9):1178-1185.
doi:10.1038/bmt.2011.254
42. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following
Targeted Oral Busulfan as Conditioning for Hematopoietic Cell
Transplantation: Pharmacokinetics, Liver Toxicity, and Mortality.Biol Blood Marrow Transplant . 2007;13(7):853-862.
doi:10.1016/j.bbmt.2007.03.012
43. Mohanan E, Panetta JC, Lakshmi KM, et al. Pharmacokinetics and
Pharmacodynamics of Treosulfan in Patients With Thalassemia Major
Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Clin Pharmacol Ther . 2018;104(3):575-583. doi:10.1002/cpt.988
44. Langenhorst JB, van Kesteren C, van Maarseveen EM, et al.
Fludarabine exposure in the conditioning prior to allogeneic
hematopoietic cell transplantation predicts outcomes. Blood Adv .
2019;3(14):2179-2187. doi:10.1182/bloodadvances.2018029421
45. Molina-Arcas M, Marcé S, Villamor N, et al. Equilibrative nucleoside
transporter-2 (hENT2) protein expression correlates with ex vivo
sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells.Leukemia . 2005;19(1):64-68. doi:10.1038/sj.leu.2403582
46. Chen S, Wainwright DA, Wu JD, et al. CD73: an emerging checkpoint
for cancer immunotherapy. Immunotherapy . Published online June
21, 2019. doi:10.2217/imt-2018-0200
47. Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B. Targeting CD73 to
augment cancer immunotherapy. Curr Opin Pharmacol . 2020;53:66-76.
doi:10.1016/j.coph.2020.07.001
48. Yu M, Guo G, Huang L, et al. CD73 on cancer-associated fibroblasts
enhanced by the A 2B -mediated feedforward circuit enforces an immune
checkpoint. Nat Commun . 2020;11(1):515.
doi:10.1038/s41467-019-14060-x
49. Allard B, Turcotte M, Stagg J. CD73-Generated Adenosine:
Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth. Dwyer
KM, ed. J Biomed Biotechnol . 2012;2012:485156.
doi:10.1155/2012/485156
50. Mohanan E, Panetta JC, Lakshmi KM, et al. A 5’UTR Polymorphism in
NT5E Gene Influences Outcome in Patients with Acute Myeloid Leukemia
Undergoing Hematopoietic Stem Cell Transplantation with Fludarabine
Based Conditioning Regimen. Blood . 2016;128(22):984-984.
doi:10.1182/blood.V128.22.984.984
51. Jiang T, Xu X, Qiao M, et al. Comprehensive evaluation of NT5E/CD73
expression and its prognostic significance in distinct types of cancers.BMC Cancer . 2018;18(1):267. doi:10.1186/s12885-018-4073-7
52. Vaisitti T, Arruga F, Guerra G, Deaglio S. Ectonucleotidases in
Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets.Front Immunol . 2019;10. doi:10.3389/fimmu.2019.02301
53. Thompson LF, Tsukamoto H, Chernogorova P, Zeiser R. A delicate
balance. OncoImmunology . 2013;2(1):e22107. doi:10.4161/onci.22107
54. Tsukamoto H, Chernogorova P, Ayata K, et al. Deficiency of
CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host
disease. Blood . 2012;119(19):4554-4564.
doi:10.1182/blood-2011-09-375899
55. Geraghty NJ, Watson D, Sluyter R. Pharmacological blockade of the
CD39/CD73 pathway but not adenosine receptors augments disease in a
humanized mouse model of graft-versus-host disease. Immunol Cell
Biol . 2019;97(6):597-610. doi:10.1111/imcb.12251
56. Bernasconi P, Borsani O. Immune Escape after Hematopoietic Stem Cell
Transplantation (HSCT): From Mechanisms to Novel Therapies.Cancers . 2020;12(1):69. doi:10.3390/cancers12010069
57. Fausther M. Extracellular adenosine: a critical signal in liver
fibrosis. Am J Physiol-Gastrointest Liver Physiol .
2018;315(1):G12-G19. doi:10.1152/ajpgi.00006.2018
58. Tiwari‐Heckler S, Jiang ZG. Adenosinergic Signaling in Liver
Fibrosis. Clin Liver Dis . 2019;14(1):1-4. doi:10.1002/cld.777